Iopamidol

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Iopamidol
Accession Number
DB08947
Type
Small Molecule
Groups
Approved
Description

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Structure
Thumb
Synonyms
  • Iopamidol
External IDs
B 15 000 / SQ 13,396 / SQ 13396 / SQ-13396
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iopamidol Injection USPSolutionIntravascularHospira Healthcare UlcNot applicableNot applicableCanada
Iopamidol Injection USPSolutionIntravascularHospira Healthcare UlcNot applicableNot applicableCanada
IsovueSolution612 mg/1mLIntravascularApothecary Shop Wholesale Inc.2011-07-012011-08-31Us
Isovue 128 Inj 26%LiquidIntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1988-12-311998-07-30Canada
Isovue 128 InjectionLiquidIntravenousBracco Imaging S.P.A.1998-01-082000-07-20Canada
Isovue 200Injection, solution408 mg/1mLIntravascularBracco Diagnostics, Inc1985-12-31Not applicableUs
Isovue 200Injection, solution408 mg/1mLIntravascularBIPSO GmbH1985-12-31Not applicableUs
Isovue 200 Inj 41%LiquidIntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1985-12-311998-07-30Canada
Isovue 200 InjectionLiquidIntravenousBracco Imaging S.P.A.1998-01-08Not applicableCanada
Isovue 250Injection, solution510 mg/1mLIntravascularBIPSO GmbH1994-10-12Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-iopamidolLiquidIntravenousPharmascience IncNot applicableNot applicableCanada
PMS-iopamidolLiquidIntravenousPharmascience IncNot applicableNot applicableCanada
PMS-iopamidolLiquidIntravenous; SubarachnoidPharmascience IncNot applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Gastromiro (Bracco) / Iopamiro (Bracco) / Iopamiron (Bayer) / Jopamiro (Bracco) / Moiopamin (Hikari Seiyaku) / Oypalomin (Fuji Yakuhin) / Solutrast (Bracco)
Categories
UNII
JR13W81H44
CAS number
60166-93-0
Weight
Average: 777.0853
Monoisotopic: 776.854094955
Chemical Formula
C17H22I3N3O8
InChI Key
XQZXYNRDCRIARQ-LURJTMIESA-N
InChI
InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
IUPAC Name
N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-1,2-dihydroxypropylidene]amino}-2,4,6-triiodobenzene-1,3-dicarboximidic acid
SMILES
[H][C@@](C)(O)C(O)=NC1=C(I)C(C(O)=NC(CO)CO)=C(I)C(C(O)=NC(CO)CO)=C1I

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AldesleukinThe risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.
MetforminThe risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Tian FX, Xu B, Lin YL, Hu CY, Zhang TY, Gao NY: Photodegradation kinetics of iopamidol by UV irradiation and enhanced formation of iodinated disinfection by-products in sequential oxidation processes. Water Res. 2014 Jul 1;58:198-208. doi: 10.1016/j.watres.2014.03.069. Epub 2014 Apr 5. [PubMed:24762552]
External Links
KEGG Drug
D01797
PubChem Compound
65492
PubChem Substance
310264913
ChemSpider
58940
ChEBI
31711
ChEMBL
CHEMBL1200932
Drugs.com
Drugs.com Drug Page
Wikipedia
Iopamidol
ATC Codes
V08AB04 — Iopamidol
AHFS Codes
  • 36:68.00 — Roentgenography
FDA label
Download (715 KB)
MSDS
Download (133 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingOtherMetastatic Castration-Resistant Prostate Cancer (mCRPC) / Metastatic Renal Cell Carcinoma / Urothelial carcinoma ureter metastatic1
1RecruitingDiagnosticLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Lung Neoplasm / Metastatic Malignant Neoplasm in the Lung / Stage IV Lung Cancer1
1, 2CompletedDiagnosticHealthy Volunteers1
2CompletedDiagnosticCoronary Artery Disease1
3CompletedDiagnosticCoronary Computed Tomographic Angiography1
4CompletedNot AvailableCIN1
4CompletedNot AvailableDrug Safety1
4CompletedNot AvailableIV Contrast Dosing1
4CompletedNot AvailableKidney Diseases1
4CompletedNot AvailablePatient Comfort and Safety1
4CompletedNot AvailableThoracic Aortic Aneurysm (TAA)1
4CompletedDiagnosticContrast Induced Nephropathy (CIN)1
4CompletedDiagnosticCoronary Artery Stenosis2
4CompletedDiagnosticPeripheral Obliterative Arteriopathy2
4CompletedDiagnosticPulmonary Embolism1
4CompletedSupportive CareContrast Agent With Lean Body Weight / Dosing Contrast Agent Using Lean Body Weight1
4CompletedTreatmentGastrointestinal Complications1
4RecruitingDiagnosticPercutaneous Coronary Intervention1
4RecruitingOtherHypothyroidism1
4TerminatedDiagnosticChronic Renal Diseases1
4TerminatedDiagnosticCoronary Artery Stenosis1
4TerminatedDiagnosticDiabetes Mellitus (DM) / Impaired Renal Function1
4TerminatedDiagnosticDiabetes Mellitus (DM) / Renal Insufficiency,Chronic1
4TerminatedOtherAcute Kidney Injury (AKI)1
Not AvailableTerminatedDiagnosticCT of the Abdomen and Pelvis With Contrast Material1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravascular
SolutionIntravascular612 mg/1mL
Injection, solutionIntravascular408 mg/1mL
LiquidIntravenous
Injection, solutionIntravascular510 mg/1mL
Injection, solutionIntravascular612 mg/1mL
LiquidIntravascular
Injection, solutionIntravascular755 mg/1mL
Injection, solutionIntrathecal612 mg/1mL
Injection, solutionIntrathecal408 mg/1mL
SolutionIntrathecal408 mg/1mL
SolutionIntrathecal612 mg/1mL
LiquidIntravenous; Subarachnoid
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.117 mg/mLALOGPS
logP-0.97ALOGPS
logP1.62ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.15ChemAxon
pKa (Strongest Basic)1.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area198.92 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity141.46 m3·mol-1ChemAxon
Polarizability55.67 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Iodobenzenes
Alternative Parents
Aryl iodides / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organoiodides / Hydrocarbon derivatives
Substituents
Iodobenzene / Aryl halide / Aryl iodide / Secondary alcohol / Carboximidic acid / Carboximidic acid derivative / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organoiodine compound, benzenedicarboxamide, pentol (CHEBI:31711)

Drug created on May 27, 2014 10:50 / Updated on November 14, 2019 19:57